Search

Author/Creator Fujiya, M

1. DOP056 Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn's disease who had lost response to anti-TNFα agents: A multicentre, open-label, Phase 1/2 study. (16th January 2018)

Authors:
Matsuoka, K; Naganuma, M; Tanida, S; Kitamura, K; Matsui, T; Arai, M; Fujiya, M; Horiki, N; Nebiki, H; Kinjo, F; Miyazaki, T; Matsumoto, T; Esaki, M; Mitsuyama, K; Saruta, M; Ido, A; Hojo, S; Takenaka, O; Oketani, K; Imai, T
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S070
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. DOP24 Japan prospective multicenter study for optimization of COVID-19 vaccinations based on the immune response and safety profile in Inflammatory Bowel Disease patients: Interim analyses of the J-COMBAT trial. (21st January 2022)

Authors:
Watanabe, K; Hisamatsu, T; Nakase, H; Nagase, K; Matsuura, M; Aoyama, N; Kobayashi, T; Sakuraba, H; Yokoyama, K; Nishishita, M; Esaki, M; Hirai, F; Nagahori, M; Nanjo, S; Omori, T; Tanida, S; Yokoyama, Y; Moriya, K; Maemoto, A; Handa, O
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i074
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. K-ras mutations and cell kinetics in Helicobacter pylori associated gastric intestinal metaplasia: a comparison before and after eradication in patients with chronic gastritis and gastric cancer. Issue 8 (22nd September 2006)

Authors:
Watari, J; Tanaka, A; Tanabe, H; Sato, R; Moriichi, K; Zaky, A; Okamoto, K; Maemoto, A; Fujiya, M; Ashida, T; Das, K M; Kohgo, Y
Journal:
Journal of clinical pathology
Issue:
Volume 60:Issue 8(2007)
Page Start:
921
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn's disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies. (30th January 2023)

Authors:
Atreya, R; Irving, P; Fujiya, M; Colombel, J F; Danese, S; Peyrin-Biroulet, L; Bessissow, T; Panaccione, R; D'Haens, G; van Haaren, S; Neimark, E; Zambrano, J; Zhang, Y; Kligys, K; Ferrante, M
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i675
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗